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Because the benefits of immune checkpoint blockade may be restricted to tumors with pre-existing immune
recognition, novel therapies that facilitate de novo immune activation are needed. DRibbles is a novel multi-valent
vaccine that is created by disrupting degradation of intracellular proteins by the ubiquitin proteasome system. The
DRibbles vaccine is comprised of autophagosome vesicles that are enriched with defective ribosomal products and
short-lived proteins, known tumor-associated antigens, mediators of innate immunity, and surface markers that
encourage phagocytosis and cross-presentation by antigen presenting cells. Here we summarize the rationale and
preclinical development of DRibbles, translational evidence in support of DRibbles as a therapeutic strategy in
humans, as well as recent developments and expected future directions of the DRibbles vaccine in the clinic.
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A successful anti-tumor immune response by cytotoxic
CD8+ T cells requires recognition of tumor antigen in
the context of MHCI molecules. One potential explan-
ation for how naïve T-cells become activated against
tumor antigens is a process called cross-presentation.
During cross-presentation, professional antigen present-
ing cells (pAPCs) phagocytose tumor proteins, digest
them with proteasomes, and present them via MHCI to
T cells for activation. Two hypothesized classes of
tumor-associated proteins—called defective ribosomal
products (DRiPs) and short-lived proteins (SLiPs)— are
produced in abundance within tumor cells, however are
inherently unstable and only expressed transiently under
physiologic conditions before being poly-ubiquitinated
and degraded by tumor cell proteosomes [1]. These
tumor-associated DRiPs/SLiPs, while expressed fre-
quently on tumor MHCI, would be inefficiently cross-* Correspondence: david.page2@providence.org
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before they reach the APCs. It has been hypothesized
that these DRiPs/SLiPs antigens, if delivered to pAPCs
for cross-presentation, could potentially facilitate anti-
tumor immune responses and could form the basis of a
novel anti-tumor vaccine.
Here, we introduce the DRibbles vaccine product, which
is produced by simultaneously blocking proteosomal deg-
radation and manipulating the cellular autophagy path-
way, leading to stabilization of DRiPs/SLiPs proteins and
formation of autophagosome microvesicles that contain
not only DRiPs/SLiPs, but also other protein products that
have been shown to facilitate cross-presentation. These
autophagosomes are then harvested by membrane disrup-
tion and fractionation to create the vaccine called DRib-
bles. Here, we summarize the preclinical data supporting
the DRibbles vaccine, translational evidence in support of
its efficacy in humans, and completed and ongoing clinical
trials of DRibbles across a variety of malignancies.In the lab: preclinical development of the
DRibbles vaccine
Evidence supporting the utility of the DRibbles concept for
priming T cell responses was first demonstrated in a seriesdistributed under the terms of the Creative Commons Attribution 4.0
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HEK 293 T tumor cell model [2]. The OVA gene was engi-
neered to produce “short-lived” OVA proteins that would
become poly-ubiquinated and degraded by proteasomes
under physiologic conditions [2, 3]. Whole cells were
treated with bortezomib (Velcade®, Takeda, Osaka, Japan)
and ammonium chloride (NH4Cl), which block proteasome
activity and lysosomal digestion of autophagosomes, re-
spectively. Then, the treated cells were mechanically dis-
rupted and fractionated by centrifugation to harvest an
autophagosome-enriched product (Fig. 1a). This product
was termed “DRibbles,” an acronym for “DRiPs and SLiPs-
containing blebs.” The short-lived OVA proteins were
found to be enriched in this DRibbles autophagosome
product, compared to non-treated cells or non-disrupted
bortezomib/NH4Cl-treated cells. Furthermore, DRibbles
vaccine was superior in priming OVA-specific T cells com-
pared to non-treated or non-disrupted cells. These data
suggested that DRibbles could be an effective vaccine
against endogenous tumor-associated short-lived proteins.
Next, the DRibbles vaccine was evaluated for in vivo
efficacy. DRibbles can either be produced based on an
autologous concept (i.e. making the vaccine from a pa-
tient’s own tumor) or an allogeneic concept (i.e. making
an “off-the-shelf” vaccine from one or more tumors to
be administered to many patients). To model the autolo-
gous concept, DRibbles vaccine was generated from aa.
b.
Fig. 1 The DRibbles vaccine product is generated by manipulating the end
that contain antigens was well as mediators of innate immunity and phago3LL Lewis lung cancer cell line and was shown to delay
tumor growth and improve survival in that cancer model
[4]. Next, to model the allogeneic concept, DRibbles vac-
cine was generated from multiple implantable methyl-
cholantherene (MCA)-induced sarcoma cell lines. The
long-standing paradigm was that whole-cell MCA vac-
cine would be effective only against homologous tumors
[5]. However, vaccination with DRibbles derived from unre-
lated MCA-induced sarcomas was also effective in slowing
tumor growth of other, independently-derived MCA sarco-
mas [3]. T cells isolated from these mice released interferon
gamma against both homologous and independently-
derived tumors, suggesting they had been cross-primed to
a broader array of antigens present across a variety of sarco-
mas. This phenomenon was called ‘cross-protection,’ and
provided evidence that an allogeneic DRibbles vaccine
might serve as an “off-the shelf” vaccine in the clinic.
Further work was conducted to characterize compo-
nents of the DRibbles vaccine. It was confirmed in various
cell lines that DRibbles contain long-lived proteins (i.e.
proteins not destined for rapid poly-ubiquitination and
degradation), and are enriched for short-lived proteins,
short-protein fragments, and poly-ubiquitinated proteins
[4]. In addition to these potential antigens, the murine
DRibbles product contained various damage-associated
molecular pattern (DAMP) signals including heat shock
proteins, high-mobility group box 1 protein (HMGB1)ogenous autophagy pathway, and is comprised of autophagosomes
cytosis
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tially mediate both adaptive and innate immunity. Finally,
the DRibbles autophagosome surfaces were found to con-
tain CLEC9A ligands, which have been shown to bind
CLEC9A receptor [6] and facilitate antigen uptake by a
subset of dendritic cells that play an important role in
cross-presentation [7] (Fig. 1b). In summary, DRibbles
was found to be composed of microvesicles that efficiently
deliver a variety of antigens to pAPCs in ways that trad-
itional liposomal and cellular vaccines do not.
Bench to bedside: translational data regarding
the DRibbles vaccine
The results of this characterization, combined with the
promise of ‘cross-protection’, led to the development of
various human DRibbles autophagosome vaccine for-
mulations for the treatment of human subjects. The
first allogeneic human DRibbles vaccine, named DPV-
001, was derived from autophagosome products of two
human cancer cell lines: UbiLT3 and UbiLT6. UbiLT3
was derived from a non-small cell lung carcinoma
(NSCLC) of mixed histology, whereas UBiLT6 was de-
rived from an NSCLC adenocarcinoma. Liquid chroma-
tography tandem mass spectrometry and western
blotting techniques have been used to quantitatively
catalogue over 2400 of the most common protein con-
stituents in DPV-001. Of these most common proteins,
there are over 25 published cancer-associated antigens,
including at least 12 proteins that are among the NCI’s
list of prioritized cancer antigens [8] such as TP53, sur-
vivin, EphA2, cyclin B1, XAGE1, Her2/neu, RhoC,
Mesothelin, Legumain, PDGFRb, FOSL1 and KRAS [9].
Whole exome sequencing was used to show that many of
the UBiLT3/6 genes are mutated or polymorphic versus the
reference human genome (hg19). Thus, the DPV-001 DRib-
bles vaccine likely contains protein variants that are foreign
to vaccinated patients. The UbiLT3/6 sequences were com-
pared to 520 unique lung adenocarcinoma sequences fromTable 1 Summary of preclinical, translational, and clinical evidence o
In the Lab
• DRibbles vaccine comprises autophagosome-packaged
cellular proteins, short-lived proteins and ribosomal proteins









• DRibbles contains innate immunity mediators
(DAMPs) and surface ligands for CLEC9a, which facilitate
uptake by APCs for cross-presentation




mutants sucThe Cancer Genome Atlas (TCGA) [10]. In addition to
containing commonly observed oncogene mutations
(for example KRAS G12C, found in 6.8 % of adenocar-
cinomas in TCGA, http://www.cbioportal.org/index.do,
accessed February 6, 2016), the UbiLT3/6 cell lines
also shared polymorphisms with the identified non-
synonymous mutations from each lung adenocarcinoma
in the TCGA. This suggests that DRibbles may serve as
an off-the-shelf vaccine against “private antigens” found
in individual patients. Furthermore, non-exact foreign
protein variants (for example other KRAS G12 codon
point mutations) may function as altered-peptide li-
gands which stimulate immune responses that spread
to a patient’s own tumor-specific neo-epitopes [11, 12].In the clinic: development of human DRibbles
vaccines
In humans, the DRibbles vaccine was first evaluated as
an autologous vaccine manufactured with tumor cells
isolated from pleural effusions of patients with NSCLC.
In this phase I clinical trial, autologous DRibbles vaccine
was found to be safe when combined with docetaxel plus
GM-CSF [13]. Autologous DRibbles vaccines, while pro-
viding a potential opportunity to vaccinate against
patient-specific neo-epitopes, have proven difficult to
manufacture consistently. Furthermore, a recent study
suggested that in melanoma patients, CD8+ T cells may
more frequently recognize non-mutated antigens such as
NY-ESO-1 and GP100, rather than neoepitopes [14].
Subsequent trials have focused on allogeneic DRibbles
products, which contain numerous non-mutated self-
antigens. Studies are underway to evaluate the role of
allogeneic DRibbles in malignancies such as prostate
adenocarcinoma and NSCLC (Table 1). These studies
are also assessing the DRibbles vaccine in conjunction
with low-dose cyclophosphamide and various adjuvants
such as topical imiquimod or GM-CSF.f the DRibbles vaccine
Bench to Bedside In the Clinic
DRibbles contains over
s, of which 25 are
r-associated antigens
• Dribbles vaccine + docetaxel was
well tolerated in a phase I NSCLC
trial
cell lines contain
f mutations and polymorphisms
nction as altered-peptide ligands
• A Phase II trial comparing
DRibbles + either GM-CSF or
Imiquimod in stage IIIA/B NSCLC
is ongoing
enocarcinoma sequence from
tabase shares at least one mutation
lymorphisms found in DPV-001




h as KRAS G12C
• DRibbles induced increased
antibody reactivity in the first 2
patients treated on a phase II trial
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are underway evaluating safety and anti-tumor efficacy
of other modulators of autophagy such as hydroxychlor-
oquine and alpha-tocopheryloxyacetic acid (alpha-TEA)
[15–17]. Besides DRibbles, there are reports of alterna-
tive potentially effective cell-derived vesicle vaccines. For
example, melanoma patients have been treated with an
autologous product of dendritic cell-derived exosomes
pulsed with tumor antigen peptides [18]. More recently,
another group has shown that tumor-derived exosomes
could be a more effective method for priming anti-tumor
immune responses compared to tumor lysate alone [19].
One major barrier for all cancer vaccine clinical trials
is the difficulty in demonstrating efficacy in early stage
disease, especially in tumor types with low recurrence
rates or prolonged latency periods. Therefore, scientific-
ally grounded immune monitoring strategies must be
used to inform early development of vaccines, allowing
for smaller trials designed to facilitate optimization of
the vaccine and perhaps identify indirect evidence of ef-
ficacy. Because DRibbles vaccines are multi-valent, and
because relevant antigenic targets may vary across pa-
tients, next-generation high-throughput technologies
such as seromic protein arrays are being used to evaluate
patient-specific immune responses and discover relevant
antigens. The phase II non-small cell lung cancer DRib-
bles adjuvant trial serves as an example of how a
seromics-based approach might be used to monitor im-
mune response. This trial was designed to detect en-
hancement in antigen-specific adaptive immunity using
serum protein arrays that measure antibody reactivity
against a panel of over 8,000 normal human protein
isoforms. The rationale is that the most robust immune
responses might be integrated with concomitant CD4 T-
helper, CD8 cytotoxic, and humoral immune responses
[20], and therefore antibody reactivity may serve to
identify antigen-specific immune responses associated
with therapy. Using the protein array, several of the 9
treated DRibbles patients were found to exhibit robust
(i.e. >10-fold increase from baseline) antibody re-
sponses to multiple antigens following vaccination [10].
Conclusion
The DRibbles vaccine serves as an excellent example
of how basic immunology research can be translated
into a promising approach in the clinic. Because the
DRibbles platform can be used to generate either au-
tologous or allogeneic vaccines derived from any
tumor cell line, it may have clinical applications across a
broad range of malignancy types. Relative to peptide and
DNA vaccines, the DRibbles autophagosome-enriched
vaccine platform may serve to vaccinate broadly against a
spectrum of antigen types including potential neo-
epitopes and a short-lived/defective cellular proteins thatmay not be present in other complex cell-derived cancer
vaccines. Additionally, molecules such as CLEC9a ligand
encourage uptake of DRibbles by cross-presenting
pAPCs—a property not present in traditional liposome or
microvesicle vaccine formulations. Because of these
unique features, the DRibbles construct may in the future
be investigated as a delivery mechanism for other vac-
cines, such as personalized patient-specific cancer neo-
epitope peptides.
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